|
Gene: TOP3A |
Gene summary for TOP3A |
Gene summary. |
Gene information | Species | Human | Gene symbol | TOP3A | Gene ID | 7156 |
Gene name | DNA topoisomerase III alpha | |
Gene Alias | MGRISCE2 | |
Cytomap | 17p11.2 | |
Gene Type | protein-coding | GO ID | GO:0000002 | UniProtAcc | Q13472 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7156 | TOP3A | HCC1_Meng | Human | Liver | HCC | 6.26e-29 | 2.26e-02 | 0.0246 |
7156 | TOP3A | HCC1 | Human | Liver | HCC | 5.70e-08 | 2.30e+00 | 0.5336 |
7156 | TOP3A | HCC2 | Human | Liver | HCC | 1.13e-15 | 3.59e+00 | 0.5341 |
7156 | TOP3A | HCC5 | Human | Liver | HCC | 1.45e-11 | 1.39e+00 | 0.4932 |
7156 | TOP3A | S027 | Human | Liver | HCC | 3.16e-02 | 3.53e-01 | 0.2446 |
7156 | TOP3A | S028 | Human | Liver | HCC | 1.04e-07 | 3.42e-01 | 0.2503 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0007059 | Liver | HCC | chromosome segregation | 197/7958 | 346/18723 | 3.57e-08 | 7.87e-07 | 197 |
GO:0051304 | Liver | HCC | chromosome separation | 53/7958 | 96/18723 | 8.05e-03 | 3.17e-02 | 53 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TOP3A | SNV | Missense_Mutation | novel | c.1838N>G | p.Tyr613Cys | p.Y613C | Q13472 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
TOP3A | deletion | Frame_Shift_Del | c.128delN | p.Asn43ThrfsTer16 | p.N43Tfs*16 | Q13472 | protein_coding | TCGA-AX-A1C4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
TOP3A | deletion | Frame_Shift_Del | c.128delA | p.Asn43ThrfsTer16 | p.N43Tfs*16 | Q13472 | protein_coding | TCGA-AX-A2HG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
TOP3A | deletion | Frame_Shift_Del | c.128delN | p.Asn43ThrfsTer16 | p.N43Tfs*16 | Q13472 | protein_coding | TCGA-EO-A22S-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
TOP3A | deletion | Frame_Shift_Del | novel | c.859delA | p.Arg287GlyfsTer11 | p.R287Gfs*11 | Q13472 | protein_coding | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
TOP3A | SNV | Missense_Mutation | novel | c.1564N>C | p.Asp522His | p.D522H | Q13472 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DD-AAE3-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TOP3A | SNV | Missense_Mutation | c.1594A>T | p.Ile532Phe | p.I532F | Q13472 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-LG-A6GG-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TOP3A | SNV | Missense_Mutation | rs144590444 | c.1424N>A | p.Arg475Gln | p.R475Q | Q13472 | protein_coding | deleterious(0.01) | probably_damaging(0.938) | TCGA-38-4625-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TOP3A | SNV | Missense_Mutation | c.452N>C | p.Arg151Thr | p.R151T | Q13472 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-38-4630-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
TOP3A | SNV | Missense_Mutation | novel | c.1214G>T | p.Arg405Leu | p.R405L | Q13472 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-44-6145-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |